Breaking News: NewAmsterdam Pharma Sets Record with $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants!
NAARDEN, The Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) —
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants,” such offering, the “Offering”). The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $416.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions.
NewAmsterdam Pharma Company N.V. is making headlines with its record-breaking public offering of ordinary shares and pre-funded warrants. This significant move is set to bring in a staggering $416.5 million in proceeds for the company, showcasing investor confidence and interest in the development of oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C levels.
The success of this offering serves as a testament to the growth and potential of NewAmsterdam Pharma, positioning them as a key player in the biopharmaceutical industry. With a focus on providing effective and well-tolerated treatments for individuals with cardiovascular conditions, the company is making strides towards addressing unmet medical needs in this critical area of healthcare.
Investors have shown great enthusiasm for NewAmsterdam Pharma’s innovative approach to developing therapies, leading to a strong response to the public offering. The funds raised will undoubtedly support further research, development, and commercialization efforts, ultimately benefiting patients in need of advanced treatment options.
How Will This Affect Me?
As an individual, this groundbreaking development in the pharmaceutical sector may indirectly impact you in the future. The advancement of new treatments for cardiovascular diseases could potentially lead to improved options for managing your own health and well-being. Additionally, the success of companies like NewAmsterdam Pharma in securing substantial funding can signify growth opportunities within the industry, potentially creating more job prospects and driving further innovation.
How Will This Affect the World?
The impact of NewAmsterdam Pharma’s record-setting public offering extends beyond financial gains for the company. The advancements made in developing non-statin medications for cardiovascular conditions have the potential to benefit individuals worldwide, offering hope for better outcomes and improved quality of life for patients at risk of CVD. The ripple effects of such innovations can lead to a positive shift in healthcare practices and contribute to raising the standard of care on a global scale.
Conclusion
In conclusion, NewAmsterdam Pharma’s successful public offering signals a significant milestone in the realm of biopharmaceutical research and development. The substantial proceeds generated will fuel further progress in creating advanced treatments for cardiovascular disease, ultimately making a positive impact on individuals’ health and well-being. As we look towards the future, the innovative efforts of companies like NewAmsterdam Pharma pave the way for a brighter and healthier world.
